McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia

被引:162
作者
Collins, Michael T. [1 ]
Singer, Frederick R. [2 ]
Eugster, Erica [3 ]
机构
[1] Natl Inst Dent & Craniofacial Res, Skeletal Clin Studies Unit, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA
[2] John Wayne Canc Inst, Director Endocrine & Bone Dis Program, Santa Monica, CA USA
[3] Indiana Univ, Sch Med, Dept Pediat, Sect Pediat Endocrinol, Indianapolis, IN 46202 USA
基金
美国国家卫生研究院;
关键词
G-ALPHA-S; GROWTH-HORMONE EXCESS; STIMULATORY G-PROTEIN; TERM-FOLLOW-UP; PRIMARY HYPERPARATHYROIDISM; SOMATOSTATIN ANALOG; ADENYLYL-CYCLASE; BONE; PATIENT; OSTEOSARCOMA;
D O I
10.1186/1750-1172-7-S1-S4
中图分类号
Q3 [遗传学];
学科分类号
071007 [遗传学];
摘要
Fibrous dysplasia (FD) is sometimes accompanied by extraskeletal manifestations that can include any combination of cafe-au-lait macules, hyperfunctioning endocrinopathies, such as gonadotropin-independent precocious puberty, hyperthyroidism, growth hormone excess, FGF23-mediated renal phosphate wasting, and/or Cushing syndrome, as well as other less common features. The combination of any of these findings, with or without FD, is known as McCune-Albright syndrome (MAS). The broad spectrum of involved tissues and the unpredictable combination of findings owe to the fact that molecular defect is due to dominant activating mutations in the widely expressed signaling protein, G(s)alpha, and the fact these mutations arises sporadically, often times early in development, prior to gastrulation, and can distribute across many or few tissues. The complexity can be mastered by a systematic screening of potentially involved tissues and cognizance that the pattern of involved tissues is established, to some degree, in utero. Thorough testing allows the clinician to establish, often times at presentation, the full extent of the disease, and importantly as well what tissues are unaffected. Treatment and follow-up can then be focused on affected systems and a meaningful prognosis can be offered to the patient and family. The authors outline screening and treatment strategies that allow for effective management of the extraskeletal manifestations of FD.
引用
收藏
页数:14
相关论文
共 69 条
[1]
Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome [J].
Akintoye, SO ;
Chebli, C ;
Booher, S ;
Feuillan, P ;
Kushner, H ;
Leroith, D ;
Cherman, N ;
Bianco, P ;
Wientroub, S ;
Robey, PG ;
Collins, MT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (11) :5104-5112
[2]
Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome [J].
Akintoye, Sunday O. ;
Kelly, Marilyn H. ;
Brillante, Beth ;
Cherman, Natasha ;
Turner, Sarah ;
Butman, John A. ;
Robey, Pamela G. ;
Collins, Michael T. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (08) :2960-2966
[3]
Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females - Report of five cases [J].
Albright, F ;
Butler, AM ;
Hampton, AO ;
Smith, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1937, 216 :727-746
[4]
Severe hyperparathyroidism associated with fibrous dysplasia: A case report [J].
Arik, N ;
Biriken, D ;
Akpolat, T ;
Sungur, C ;
Coskun, C ;
Basoglu, T ;
Keskin, M ;
Sahin, M ;
Toller, MO .
NEPHRON, 1996, 74 (02) :481-482
[5]
Platelet dysfunction and increased bleeding tendency in McCune-Albright syndrome [J].
Bajpai, Anurag ;
Greenway, Anthea ;
Zacharin, Margaret .
JOURNAL OF PEDIATRICS, 2008, 153 (02) :287-289
[6]
Acromegaly and cancer risk: a cohort study in Sweden and Denmark [J].
Baris, D ;
Gridley, G ;
Ron, E ;
Weiderpass, E ;
Mellemkjaer, L ;
Ekbom, A ;
Olsen, JH ;
Baron, JA ;
Fraumeni, JF .
CANCER CAUSES & CONTROL, 2002, 13 (05) :395-400
[7]
BENJAMIN DR, 1973, ARCH PATHOL, V96, P175
[8]
Beuerlein ME, 1997, ARCH OTOLARYNGOL, V123, P106
[9]
Blanco P, 1999, REV RHUM, V66, P177
[10]
BNEDICT PH, 1962, METABOLISM, V11, P30